

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – December 14, 2016 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

A. November 9, 2016 DUR Minutes – Vote

B. November 9, 2016 DUR Recommendations Memorandum

C. Correspondence

Items to be presented by Dr. Holderread, Dr. Adams, Dr. Abbott, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Chronic Medication Adherence Program Update – See Appendix B

A. Medication Coverage Activity for November 2016

B. Pharmacy Help Desk Activity for November 2016

C. Chronic Medication Adherence Program Update

Items to be presented by Joseph Young:

5. Action Item – Proposed Executive Session as Recommended by the Office of Legal Services and Authorized by the Open Meetings Act, 25 O.S. § 307(B)(4) – Discussion of Pending and Potential Litigation/Claims

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Acticlate® (Doxycycline Hyclate) – See Appendix C

A. Introduction

B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Jadenu™ (Deferasirox) and Ferriprox® (Deferiprone) – See Appendix D

A. Introduction: Oral Iron Chelating Agents

B. Estimated Cost Savings: Oral Iron Chelating Agents

C. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Pancreaze® (Pancrelipase), Pertzye® (Pancrelipase), and Viokace® (Pancrelipase) – See Appendix E

A. Introduction

B. Pancreatic Enzyme Product Summaries

C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize BromSite™ (Bromfenac 0.075% Ophthalmic Solution)

– See Appendix F

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Ratterman, Dr. Muchmore, Chairman:

10. Annual Review of Hepatitis C Medications and 30-Day Notice to Prior Authorize Viekira XR™ (Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir) and Epclusa® (Sofosbuvir/Velpatasvir)

– See Appendix G

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Hepatitis C Medications
- D. Prior Authorization of Hepatitis C Medications
- E. Market News and Updates
- F. Regimen Comparison
- G. Viekira XR™ (Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir) Product Summary
- H. Epclusa® (Sofosbuvir/Velpatasvir) Product Summary
- I. College of Pharmacy Recommendations
- J. Utilization Details of Hepatitis C Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

11. 30-Day Notice to Prior Authorize Exondys 51™ (Eteplirsen) – See Appendix H

- A. Duchenne Muscular Dystrophy
- B. Exondys 51™ (Eteplirsen) Product Summary
- C. Market News and Updates
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

12. Annual Review of Otic Anti-Infective Medications and 30-Day Notice to Prior Authorize Otovel® (Ciprofloxacin/Fluocinolone Acetonide) – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of Otic Anti-Infective Medications
- C. Prior Authorization of Otic Anti-Infective Medications
- D. Market News and Updates
- E. Otovel® (Ciprofloxacin/Fluocinolone Acetonide) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Otic Anti-Infective Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

13. Annual Review of Maintenance Asthma & Chronic Obstructive Pulmonary Disease (COPD) Medications & 30-Day Notice to Prior Authorize Cinqair® (Reslizumab) and Bevespi Aerosphere® (Glycopyrrolate/Formoterol Fumarate) – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Maintenance Asthma and COPD Medications
- C. Prior Authorization of Maintenance Asthma and COPD Medications
- D. Market News and Updates
- E. Cinqair® (Reslizumab) Product Summary
- F. Bevespi Aerosphere® Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Maintenance Asthma and COPD Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

14. Annual Review of Anti-Emetic Medications and 30-Day Notice to Prior Authorize Syndros™ (Dronabinol), Sustol® (Granisetron), and Bonjesta® (Doxylamine/Pyridoxine) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Emetic Medications
- C. Prior Authorization of Anti-Emetic Medications

- D. Market News and Updates
- E. Syndros™ (Dronabinol) Product Summary
- F. Sustol® (Granisetron) Product Summary
- G. Bonjesta® (Doxylamine/Pyridoxine) Product Summary
- H. College of Pharmacy Recommendations
- I. Utilization Details of Anti-Emetic Medications

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

15. Annual Review of Phosphate Binders and 30-Day Notice to Prior Authorize Fosrenol® (Lanthanum Carbonate), Velphoro® (Sucroferric Oxyhydroxide), and Auryxia™ (Ferric Citrate) – See Appendix L

- A. Introduction
- B. Utilization of Phosphate Binders
- C. Market News and Updates
- D. Phosphate Binders Product Comparison
- E. Fosrenol® (Lanthanum Carbonate) Product Summary
- F. Velphoro® (Sucroferric Oxyhydroxide) Product Summary
- G. Auryxia™ (Ferric Citrate) Product Summary
- H. College of Pharmacy Recommendations
- I. Utilization Details of Phosphate Binders

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

16. 30-Day Notice to Prior Authorize Defitelio® (Defibrotide Sodium) – See Appendix M

- A. Hepatic Venous Occlusive Disease (VOD) Background Information
- B. Defitelio® (Defibrotide Sodium) Product Summary
- C. College of Pharmacy Recommendations

Non-presentation; questions only:

17. Annual Review of Testosterone Products – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Testosterone Products
- C. Prior Authorization of Testosterone Products
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Testosterone Products

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

18. FDA and DEA Updates – See Appendix O

Items to be presented by Dr. Holderread, Dr. Abbott, Dr. Muchmore, Chairman:

19. Future Business* (Upcoming Product and Class Reviews)

No Meeting Scheduled for January 2017

- A. Seizure Medications
- B. Botulinum Toxins
- C. Kanuma™ (Sebelipase Alfa)
- D. Parkinson's Disease Medications
- E. Xuriden™ (Uridine Triacetate)
- F. Anti-Migraine Medications
- G. Hyperkalemia Medications
- H. Actinic Keratosis Medications

**Future business subject to change.*

20. Adjournment